🔴 Incyte is trading 4.19% down in pre-market; no confirmed company-specific catalyst

Incyte is trading at $108.34, down -4.19% in pre-market, with no verified company-specific announcement directly explaining the October 19 decline.

• Incyte announced upcoming oncology data presentations at ESMO, scheduled for October 23–27; this is forthcoming news, not an identified explanation for the decline.
• An October 19 sector report said XBI fell 6.2%, which may be a factor but does not establish a direct cause for Incyte’s move.